Question 1: Tell us about how and when you discovered nanobacteria.

Our colleagues and Nobel Prize Nominee Medical Researchers, Neva Ciftcioglu, PhD and Olavi Kajander, MD, PhD, (Microbiology Department-University of Kuopio, Finland) were working on several medical research projects in 1992 using mammalian cell cultures. They became frustrated because their mammalian cell cultures kept dying. Mammalian cell cultures and most all human biologicals are normally grown in fetal bovine serum (FBS) and cell culture death is a common problem in medical research that forces researchers to start entire projects over again and again.

Well, this time instead of just discarding the dead mammalian cell cultures, they just left them in the incubator and subsequently forgot about them. Approximately four months later finding the old cultures, they realized that an unusual thin slimy film had developed on the culture surfaces. Well, since scientists are by nature as inquisitive as cats, Drs. Ciftcioglu and Kajander they couldn’t resist full evaluation of this unusual slime. They were not able to determine the nature of the film using the highest power light microscopes, so they used Scanning Electron Microscopes and Transmission Electron Microscopes from lowest to highest magnification (100,000X).

Lo and behold! They found these 20-200 nanometer sized nanobacteria in calcified shells: The bacteria in the stone! They had never seen anything like them, and nothing like them had ever been seen or described in the microbiology world.

These nanobacteria are structurally and physiologically unique in many ways: they are 20-200 nanometers in size, they have a unique “cellular” structure and membrane structure like nothing else on earth, they replicate very slowly (every 3-5 days) and by different methods, they are pleomorphic, meaning that they assume different life forms for different phases and activities of their lives, they can go dormant in a self-made calcium shell, they are saprophytic in humans, they are “the toughest of bugs” resistant to being killed both In-Vitro and In-Vivo and they are the cause of many human diseases. They are structurally and functionally simplistic, unbelievably small and genetically unique.

Although nicked-named by one reporter as “Conan the Bacterium”, Drs. Ciftcioglu & Kajander formally named this novel pleomorphic nanobacteria that thrives in our blood, Nanobacterium sanguineum.

Question 2: How long have you been studying nanobacterium sanguineum? Has there been any gene sequencing?

This serendipitous and huge discovery was the beginning of what was to become life-dedicated research on nanobacteria. Because of the fundamental uniqueness of these nanobacteria, the basic science on it continues today, with involvement of nanobacterial researchers all over the world at prestigious universities and research facilities.

Today, after 10 years of intensive and exhausting research, we know a great deal about these unique pathogenic disease-causing nanobacteria and how they cause human diseases. The gene-sequencing done originally by Drs. Ciftcioglu and Kajander has been successfully replicated by five nanobacterial research groups that I am aware of and there are definitely unique findings (new peptides) involved in the genetic sequence.

Question 3: How many different types of nanobacteria are there? In what ways do nanobacteria differ from larger bacteria?

NanobacLabs Researcher, Dr. Neva Ciftcioglu is currently at the NASA Johnson Space Center on a one year sabbatical doing nanobacterial research on the astronauts. It appears that nanobacteria “go wild” in zero gravity and the astronauts have an unusually high incidence of kidney stones, calcified coronary artery disease, arthritis and other disorders involving pathological calcification. NASA is more than just casually interested in finding out about these nanobacteria, especially since the geological discovery of finding nanobacteria in the martian Allende rock.

For the purposes of this interview, I would like to downplay this aspect of research at this time. It is clearly “good press” and sensational, but the research is not done yet and we need to focus on the eradication of the human disease caused by these nanobacteria: Heart Disease, Kidney Disease, and many others...

Question 4: How much do we currently know about nanobacteria?

What is most important at this time is that Nanobacterium sanguineum has been shown by multiple researchers to be a unique organism that causes pathological “disease” calcification in humans. In other words, it is the calcification that we find in the human body that we were not “born with“. These nanobacteria secrete a slimy calcium biofilm around themselves that subsequently hardens, creating a calcium shell “igloo” around them. They are able to build upon themselves in this calcified form like coral formation.

When we look at pathological calcification in humans (coronary artery heart plaque, vascular plaque, soft tissue calcifications, kidney stones, PKD, arthritis and others) what we are actually seeing is calcified nanobacteria in concretion-like colonies. No human tissue is resistant to nanobacteria; they easily cross the blood-brain barrier to cause brain calcification disorders and “brain sand”. They cause “apoptosis” or cell-death in any and all tissues they contact. They alter RNA and DNA and transcription expression. To our knowledge, they are ubiquitous and are everywhere. We have no defense mechanism against them. They cause production of human antibodies in response to their biofilm, but when our cellular defense systems arrive, they cannot “see” anything because the nanobacteria are too small; it’s like fighting a war against invisible men. Our immune hyperalert process resultant from nanobacterial biofilm causes chronic inflammation in our tissues affected by the nanobacteria. Most human degenerative disease processes have been associated with chronic pathological calcification, but they were misunderstood by physicians and medical researchers as a natural process of human degeneration or aging. Now we know better.

Because of the fact that nanobacteria only replicate every three to five days and their nano size, it takes approximately 35-40 years for a human to become symptomatic from them, even if infected at birth. These factors have led us to not discover these pathogens for all of this time: incredibly small nano size, undetectable with light microscopes and incredibly slow growth rate. From our myopic viewpoint, if we were unable to detect it with medical light microscopes, we assumed there were no pathogens present; the blood was sterile. Wrong.

Question 5: When did you make the connection between human calcification related diseases and nanobacterial treatment?

NanobacLabs’ medical research work on human calcification disorders and nanobacterial treatment began after learning about nanobacteria. It was my hypothesis that Nanobacterium sanguineum caused all pathological calcification in humans that let me to develop a prescription medication to eradicate nanobacterial calcification. I personally designed the medical treatment based on the properties I learned were necessary to eradicate nanobacteria in culture form outside of the body.

Our Nobel Prize Nominee Researchers, Drs. Ciftcioglu and Kajander, have been collaborators for many years. One of their most recent published discoveries is that nanobacteria are a contaminant in IPV polio vaccines that we give our children. They suspect that all human biologicals developed in fetal bovine serum are contaminated, as cows are one of the known vectors of nanobacteria. They continue to work on the basic science associated with the nanobacteria organism, while NanobacLabs works on the medical research and treatment side.

Question 6: What is NanobacTX? How effective is it?

Our human nanobacterial research and the discovery of how to safely and effectively eradicate pathologically calcified nanobacteria is literally forging new medical frontiers. We have scientific proof that we are eradicating the calcified and soft plaque that cause heart disease with our prescription NanobacTX. We anticipate that the results from our Western IRB Monitored NanobacTX-ACES Cardiology II Study done by Board-Certified Cardiologists will be published in the Cardiology Journals in Mid-2002. Additionally, the core technology of NanobacTX is currently being used in other formal medical research studies to eradicate the pathological calcification associated with Kidney Stones, Polycystic Kidney Disease (PKD), Chronic Prostatitis, Benign Prostatic Hyperplasia (BPH) and associated with neurodegenerative disorders such as Autism, Alzheimer’s and Multiple Sclerosis. Our safe and effective prescription treatment is called “NanobacTX”. Our medical diagnostic blood tests for nanobacterial antigen and antibodies is called “NanobacTEST”. Both are currently available by physician prescription from our participating medical clinical researchers throughout the world.

Question 7: What are your plans for the future?

This is what I see for our future:
∙ Recognition of Nanobacterium sanguineum as the #1 cause of degenerative diseases.
∙ Widespread use of our NanobacTX in the treatment of heart disease.
∙ Heart Disease becomes a rare cause of death. Heart Surgery done only for emergencies.
∙ NanobacLabs development of treatment and protocols for most degenerative disease states.
∙ Proactive/preventive use of NanobacLabs regimens in middle-aged asymptomatic populations.
∙ Routine annual blood testing with NanobacTEST for Nanobacteria at birth and at all ages.
∙ Development of synthetic mammalian culture media for research.
∙ Worldwide use of 20 nanometer particle size filters in the development of human vaccines & biologicals.